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Background: Gestational diabetes mellitus (GDM) is a common medical problem associated with 
maternal and fetal complications. Good glycaemic control is the cornerstone of treatment. 
Objective: Compare outcomes between four times (4x) and twice daily (2x) regimens. The 
morning dose of the 2x regimen contained two thirds of the total insulin comprising one third 
human regular insulin and two thirds human intermediate insulin; equal amounts in the evening. 
Methods:  480 women at > 30 weeks with GDM with failure to control blood glucose randomly 
assigned to either regimen. Results: Mean time to control of blood glucose significantly less and 
glycaemic control significantly increased with 4x regimen. Operative deliveries, extent of neonatal 
hypoglycaemia, babies with low Agpar scores and those with hyperbilirubinaemia significantly 
higher in 2x daily regimen. Conclusion: 4x daily regime associated with improved fetal and 





Gestational diabetes mellitus (GDM) is defined as glucose intolerance during pregnancy. In most 
women who develop GDM, onset begins in the third trimester of pregnancy. Studies have 
recorded an incidence between 2 to 5% of pregnancies in the UK, with its prevalence rising (1). 
 A recent study conducted in Pakistan found a lower prevalence at <1% of pregnancies. In this 
study the mean Body Mass Index (BMI) and age were 24 kg/m2 and 22 years respectively, and 
all women were primigravidae (2). However an earlier study by Akhter et al showed a higher 
prevalence at 3.3% among Pakistani women (3). Rates in the US appear higher, with GDM seen 
among 8-9% of all pregnancies, with rates potentially doubling in populations at high-risk for type 
2 diabetes (4). The highest prevalence of mothers with GDM are seen among South Asian and 
black Caribbean mothers, reaching up to 14% (5,6).  
 
The National Institute for Health and Care Excellence in the UK currently recommends that 
women with potential risk factors including glycosuria, age > 30 years, obesity, past history of 
GDM or glucose intolerance, or belonging to an ethnic group at high risk of GDM, be offered 
testing for GDM in the form of an oral glucose tolerance test (7). 
  
 
The International Association of Diabetes and Pregnancy Study Groups (IADPSG) recommends 
XVLQJD³RQH-VWHS´-gram OGTT to diagnose GDM (8,9): 
 
x TIME x PLASMA GLUCOSE* 
x Fasting x PJGOPPRO/ 
x 1-hour x PJGOPPRO/ 
x 2-hour x PJGOPPRO/ 
 
The principal features of foetal and neonatal complications in pregnant women with GDM are 
macrosomia, neonatal hypoglycaemia, perinatal mortality, congenital malformations, 
pyperbilirubinaemia, polycythemia, hypocalcaemia and respiratory distress syndrome (RDS) in 
the newborn, marked by dyspnea with cyanosis. RDS usually occurs in newborn babies who are 
pre-term, have diabetic mothers and who are delivered by caesarean section. However, 
sometimes there are no apparent predisposing causes (10-13). Maternal complications include 
hypertension, preeclampsia, and an increased risk of a lower (uterine) segment Caesarean 
section (LSCS) (14-16). Hypoglycaemia should be avoided as it can cause shakiness, 
nervousness, sweating, chills, irritability, confusion including delirium, rapid heart beats ,hunger 
and nausea, headache, fatigue, anger, nightmares, seizures and potentially unconsciousness. 
 
Attempts to normalize blood glucose concentrations in pregnant mothers with GDM has become 
the cornerstone of treatment, with intensification of glucose monitoring as well as insulin 
administration improving perinatal outcomes(17,18).  
No differences in neurodevelopmental outcome were seen in 2-year-old children born to mothers 
with GDM treated with insulin or metformin during pregnancy (19).  Most prospective trials 
involving insulin therapy in women with GDM have also shown a reduction in the incidence of 
neonatal macrosomia (17, 20,21). Mothers diagnosed with GDM should also have their blood 
pressure regularly monitored, undertake exercise and undergo nutrition counselling to help 
maintain normal glycaemia levels. In patients with well controlled diabetes, there is no need to 
expedite delivery before 40 weeks of gestation.  In mothers who require insulin, or have other co-
morbid conditions, it is appropriate to begin antenatal screening with a non stress test and an 
amniotic fluid index at 32 weeks gestation.  
 
With respect to insulin therapy, our impression is that an insulin regimen administered four times 
a day is neither complicated nor more expensive, and may provide better outcomes for mothers 
and babies, compared to twice daily regimens. In addition, may cost less. Such studies have 
been undertaken by other researchers in other countries i(22,23). However, we wanted to 
research this among a population in Pakistan since to the best of our knowledge such research 
has not been undertaken in this country before.  Consequently, the objective of this study is to 
compare foetal and maternal outcomes of mothers with GDM receiving twice daily versus four 
times daily insulin regimen when diet and exercise had failed to control blood glucose levels over 
one to two weeks. Subsequently use the findings to provide future direction to key stakeholder 




This quasi experimental study was conducted prospectively from June 2014 to September 2015 
in the Obstetric ward at Holy Family hospital, Rawalpindi, Pakistan. The Holy Family hospital is 
the biggest hospital in the region serving a population of 5 million for ante natal care, and 
undertaking approximately 100-150 deliveries daily. 
  
We calculated based on previous studies, coupled with the limitation of only conducting this study 
in a single hospital and an envisaged informed consent rate of approximately 50%, that we 
needed to approach 1000 mothers with GDM meeting the inclusion criteria for their consent to 
take part in the study.. 
 
Inclusion criteria included a singleton gestation and gestational age of 30 weeks or above. 
Random blood glucose testing (RBG) as well as fasting blood glucose (FBG) levels were 
subsequently  used to help diagnose GDM. GDM was determined as follows: 100g oral glucose 
ingestion followed by at least two serum glucose concentration values equal to or above 5.9,10.6, 
9.2, 8.1 mmol/l at 0,1,2 and three hours respectively, or by the 75gm oral glucose tolerance test 
using the IADPSG criteria for diagnosis of GDM ± the one step 75 gm OGTT (8,9) - with similar 
levels at fasting and two hours. Additional tests included glycosuria (++) on urine examination, 
abnormal glycosylated haemoglobin (> 6.1%) and booked as well as non-booked patients.  
 
Mothers with congenital anomalies of their foetus and having other medical disorders including 
pre ± existing diabetes were excluded from this study.  
 
After informed consent, WKHPRWKHU¶Vhistory was taken, This included their age, parity, gestational 
age, and the presence of any other associated maternal diseases. There was also a general 
physical examination, which included their blood pressure, pulse, temperature, and respiratory 
rate. The abdominal examination included the fundal height, lie of the foetus and its presentation 
as well as the foetal heart sounds.  
 
Details regarding the mother¶s complete blood picture, chemistry, fasting blood glucose, two 
hours postprandial, two hours post lunch, two hours post dinner, urinalysis and HbA1C levels 
were also obtained prior to delivery. Foetal monitoring was carried out via a foetal kick count 
chart. There were also serial ultrasounds scans to determine the extent of foetal growth. A 
biophysical Profile and an amniotic fluid index score were also performed. Severe maternal 
hypoglycoemia was particularly noted.  
 
The main foetal outcome measures were Apgar scores at 0 and 5 minutes, presence of 
hypoglycaemia, extent of glycaemic control, presence of hyperbilirubinemia and birth weight.  The 
main maternal outcome measures included hypoglycaemia, extent of glycaemic control, mean 
time taken in both regimens to control blood glucose level and the extent of operative deliveries. 
 
Insulin regime and dietary recommendations 
 
Mothers who failed to have their blood glucose levels controlled on diet and exercise were 
randomly assigned to receive either the twice daily or four times daily insulin regimen by means 
of a computer generated random table.   
 
For mothers allocated to the twice daily regimen, the morning dose contained two thirds of their 
total daily insulin with the afternoon dose the remainder. The morning dose comprised one third 
human regular insulin (Actrapid, Novo Nordisk) and two thirds human intermediate insulin 
(Insulated, Novo Nordisk), with the evening dose comprising equal amounts of regular and 
intermediate insulin.  
 
Insulin was started with a minimum dose of 10 units. Adjustments to the insulin dose were 
subsequently  individualized for the total amount of insulin as well as the ratios between the 
insulins aFFRUGLQJWRWKHPRWKHUV¶ response,. For mothers allocated the four times daily insulin 
regimen, the first three doses of regular insulin were given by insulin pen (Novopen 3, Novo 
Nordisk) half an hour before each main meal, and the fourth dose of intermediate insulin was 
given before bed time. 
 
 The dietary recommendations for all women were 0.13 ± 0.15 MJ/ kg of their ideal body weight, 
given as three meals and three snacks daily, comprising 55% carbohydrate, 20% protein, and 25 




Glycaemic control was assessed by glucose monitoring and by monthly measurements of 
HbA1C. Capillary whole blood glucose was measured by the glucose kinase methods when 
women were admitted to hospital and by self monitoring glucose reflectance meters at home 
(Accutrend, Accucheck). VDOXHVZHUHYHULILHGE\WKHJOXFRPHWHU¶VPHPRU\ 
 
In both groups. six measurements were taken daily until adequate control was achieved. 
Thereafter, measurements were taken monthly for three months or until the baby was delivered. 
Goals for glycaemic control were blood glucose concentration of 3.5 ± 5.9 mmol/L before meals 
(22), 6.7 mmol/L or less 2 hours after meals and mean daily values of 4.4 ± 5.3 mmol/L. The 
upper values served as the threshold for initiation of insulin or an increase of the dose. Mean 
glucose levels were calculated over an 11 hour period. 
 
The aim for HbA1C concentration was below 6%. Hypoglycemia was characterised by abnormally 
low blood glucose  levels <70 mg/dl, Severe maternal hypogycemia was characterized by blood 
glucose levels of 35-40mg/dl, and can lead to confusion, disorientation, convulsions , fitting , 
seizures, intense nightmares whilst asleep and loss of consciousness and coma. This typically 




An important objective was for the fetuses to be delivered at term. The timing of any induction of 
labour was determined by an overall assessment of maternal and fetal risk factors including poor 
compliance, suboptimal glycaemic control, vasculopathy, macrosomia, suspicious fetal 
biophysical test and a poor obstetric history. Patients with an uncomplicated GDM and an 
unfavourable cervix were allowed to await until spontaneous onset of labour. Delivery was 
induced if there was a favourable cervix at 38 ± 41 wks gestation or if the patient had not 
delivered by 41 wks. Treatment was individualised for those women with gestational diabetes 
whose pregnancy was complicated. The aim for glucose concentration was 4 ± 5 mmol/L during 
labour and delivery.  
 
At delivery, the neonate was attended by the neonatal staff with Agpar scores determined at 0 
and 5 minutes. Blood samples were taken six times during the first day of life for measurement of 
plasma glucose concentration, and serum bilirubin was measured 1 ± 3 times from the first day of 
life. Serum bilirubin up till 1 mg/ dl was seen as normal with random blood glucose levels uptil 40 
mg/dl seen as normal as well. If indicated, neonates were admitted to Neonatal ICU for dextrose 




All information collected was recorded in a pre ± designed questionnaire. The data was entered 
on SPSS Version 10 for statistical analysis. SWXGHQW¶VW-test was used to compare mean time 
taken to control blood glucose levels, Chi square test was used for glycaemic control, operative 
deliveries, Apgar Scores, birth weight, neonatal hypoglycaemia and hyperbilirubinaemia. 
Statistical significance was assigned to p-value < 0.05. The variables studied included gestational 
age in weeks, mean time taken to control blood glucose levels, glycaemic control, mode of 
delivery and neonatal outcome such as Apgar Scores, birth weight, neonatal hypoglycaemia and 
hyperbilirubinaemia. 
 





480 mothers were eventually recruited equating to a 48% acceptance rate. 240 mothers with 
GDM subsequently received the twice daily insulin regimen and 240 received the four times 
insulin regimen.  
 
The mean age of the mothers with GDM  was 32 +/- 6 years, with gestational ages more than 30 
weeks (term pregnancies), The BMI of the mothers was between 29 and 35. There were few 
primigravida with most mothers being mutipara having three or more children. Baseline glycemic 
levels were: fasting>110 mg/dl, post prandial >140 mg /dl and baseline HbA1C levels >6.1%. 
There were no significant differences in the case mix of the groups of mothers and in the 
frequency of background factors known to be associated with adverse outcome of pregnancy.  
 
All were term pregnancies at more than 37 weeks of gestation with no premature deliveries. The 
mean mirth weight was 3.45kg with no small for gestational age babies and no large for 
gestational age (LGA) babies. There was no macrosomia, no intrauterine deaths, no pregnancy 
induced hypertension (PIH) and no pre-eclampsia (PET). 
 
The mean time interval to the control blood glucose levels is shown in Table 1. Overall, the mean 
time taken to control blood glucose levels was significantly less in patients who received the four 
times regimen compared to those who received twice daily insulin regimen (p=0.001 - Table 1).  
 
Table 1: Mean time (hrs) taken to control blood glucose levels  
 
 




Mean time taken to 
control blood 
glucose level 
4.4 -5.3 mmol/l  






more than 5.3 
mmol/l 






Glycemic control as reflected in the mean daily concentration of glucose (Table 2) was 
significantly better with the four times insulin regimen compared to the twice daily regimen 
p=0.001 (Table 2). 176 mothers who received the four times regimen had better glycaemic 
control compared to only 16 mothers who received twice daily regimen (73.3% vs. 6.6%). In 
addition, only 64 mothers did not achieve glycaemic control in four times regimen compared with 
184 with the twice daily regimen.  
 
Table 2: Extent of Glycemic Control 
 











4.4-5.3 176 16 192 222.22 0.001 250.17 0.001 1 
>5.3 64 224 288 
Column Total 240 240 480      
 
A higher mean dose of insulin was given to mothers who received insulin four times daily; 
however, without an increase in episodes of severe maternal hypoglycemia. 192 patients in the 
four times regimen group had an episode of hypoglycemia during the course of the study 
compared to 80 patients in twice daily regimen group (p. 0.001) (Table 3) - (80% Vs 33.3%). 
However, overall glycemic control was improved in the four times daily regimen group (Table 2). 
 















Yes 192 80 272 106.43 0.001 111.14 0.001 1 
No 48 160 208 
 240 240 480      
 
A statistical difference was found between the two groups regarding the method of delivery (Table 
4) with 72 mothers in the four times daily regimen undergoing LSCS compared to 120 patients in 
twice daily regimen. However, there was no difference in the extent of pregnancy induced 
hypertension between the two insulin groups. 
 










p value df 
MoD Svd 168 104 272 43.06 0.001 49.51 0.001 2 
Lscs 72 120 192 
 inst 0 16 16      
 240 224 480      
NB: Svd = spontaneous vaginal delivery, Lscs = Lower caesarean section and inst = instrumental delivery 
 
Among the women with GDM receiving the twice daily regimen, emergency caesarean sections 
were performed in 30% with 20% elective. The indications for elective caesarean sections were 
two or three previous scars. 
 
Tables 5 to 7 summarize the neonatal outcome data. In neonates born to mothers with GDM, the 
most prevalent complications of hypoglycaemia and hyperbilirubinaemia were lower in neonates 
whose mothers received the four times daily regimen compared with twice daily regimen.  
 
16 babies in the four times daily regimen group had hypoglycemia versus 136 in the twice daily 
regimen group hypoglycaemia(6.6% Vs 56.6%), which was statistically significant (p=0.001). 224 
neonates did not have hypoglycaemia in the four times daily regimen, compared with only 104 
neonates in the twice daily regimen (p=0.001) - Table 5.  
 
Table 5: The extent of hypoglycemia in neonates 
 








p value df 
Hypoglycaemia <40 16 136 152 138.64 0.001 153.36 0.001 1 
>40 224 104 328 
  240 240 480      
 
40 neonates in the four times daily regimen group had hyperbilirubinaemia versus 136 in the 
twice daily group (16.6% Vs 56.6%), which was statistically significant (p=0.001). 200 neonates 
did not have hyperbilirubinaemia in four times daily group compared to 104 in the twice daily 
regimen group (p=0.001) - Table 6. 
 
 Table 6: Hyperbilirubinemia among neonates 
 


















40 136 176 82.6
8 
0.001 86.17 0.001 1 
<
1 
200 104 304 
  240 240 480      
 
There was a statistically significant difference in the Apgar scores (A/S) of neonates (Table 7) 
between the two regimens. 224 neonates in the four times daily regimen group had a A/S > 7 / 10 
versus 68 in twice daily regimen, which was statistically significant (p=0.001). 16 neonates in four 
times group had A/S < 7 / 10 compared with 104 babies in twice daily group.  
 
Table 7: Apgar Score of neonates 
 















>7/10 224 136 360 86.04 0.001 93.84 0.001 1 
<7/10 16 104 120 
 240 240 480      
 
There was no statistically significant difference in birth weight of babies born to mothers in either 




In this study, intensive blood glucose monitoring as well as various other factors were used to 
evaluate which of the two insulin dose regimen would provide better overall outcomes for both 
mothers and babies in mothers with GDM. 
 
With respect to the babies born, mothers with GDM who received the four times daily insulin 
regimen had a significant reduction in the rate of neonatal hypoglycemia (6.6% Vs 56.6%) ± 
Table 5, and hyperbilirubinemia (16.6% Vs 56.6% - Table 6) versus those mothers administering 
the twice daily regimen. The reduction in the rate of both hypoglycaemia and hyperbilirubinaemia 
among neonates resulted from the significant improvement in glycaemic control in mothers 
(73.3% Vs 6.6% - Table 2). This in turn resulted from an increase in the mean dose of insulin 
administered. Our findings are in agreement with those of others(24-27) who found that 
administrating the four times daily regimen in pregnancy improved glycaemic control and 
perinatal outcomes without risk to the mother except for hypoglycaemia. However, this did not 
lead to severe hypoglycaemia. In our study, women who received the four times daily regimen 
also had more episodes of hypoglycaemia (Table 3). However, glycemic control was improved in 
the four times regimen (Table 2), and overall there was no difference in the birth weight of infants 
with either regimen. This was in agreement with the study by Price et al (28), although contrasted 
with the findings of DeVeciana et al (29).  These authors found that the four times daily regimen 
did lead to a further reduction in the incidence of large babies, i.e. with birth weights greater than 
4kg or a birth weight greater that the 90% centile. 
 
Overall, this study showed that the four times daily regimen of insulin provided a significantly 
better outcome for mothers with GDM in terms of a significantly greater chance of a vaginal 
delivery, and a correspondingly lower chance of an instrumental delivery or LSCS (Table 4). 
Neonates also had significantly higher agpar scores and a significantly lower chance of 
hyperbilirubinaemia (Tables 6 and 7). The improvements in outcomes with the four times daily 
regimen is in agreement with the findings of Konje et al (22). The four times daily regimen was 
 also marginally less expensive at 789PKR (US$7.44) versus 799PKR (US$7.53) for the twice 
daily regimen. In addition, the four times daily regimen contains only one type of insulin. This 
contrasts with the twice daily regimen where there are frequent changes in the ratio of  each 
injection, which can be cumbersome for the patient. This finding is in agreement with the those of 
Nachum et al (24). 
 
 
We are aware that our study was carried out within a single hospital in Pakistan. However, we 
believe that in view of the large number of mothers with GDM enrolled, and the highly significant 
results that we saw in a number of key maternal and foetal outcome parameters between the two 
regimes, that the findings should be applicable to other women with GDM in Pakistan. We are 
also planning further studies to substantiate the observations seen as well as look at different 




The results of this study suggests that compared with the twice daily insulin regimen, the four 
times daily insulin regimen for GDM patients results in significantly improved fetal and maternal 
outcomes across a range of measures including reduced operative deliveries alongside improved 
Agpar scores of babies, neonatal hypoglycemia, and neonatal hyperbilirubinemia. The four times 
daily regimen may be associated with greater maternal hypoglycemia;  however  this was not 
severe enough to cause symptoms and overall glycemic control was significantly better with the 
four rimes daily regimen. As a result, the four times daily regime should increasingly be used in 
Pakistan, assisted by lower costs. We will be looking to substantiate this in future studies 




1. Gestational Diabetes Mellitus (GDM) is a common medical problem worldwide, with mothers 
from South Asia and black Caribbean women at particular risk with a prevalence up to 14% of 
all mothers 
 
2. All women with risk factors for GDM should be offered 2- hours 75gm OGTT at 24-28 weeks 
of pregnancy. Women who have had GDM in a previous pregnancy should be screened 
much earlier at 16 -18 weeks. 
 
3. Patients not meeting FBS<95mg/dl and 2hrs post prandial blood glucose levels <120mgdl 
with dietary changes should begin insulin therapy. 
 
4. Antenatal screening should begin in such patients at 32 weeks with non stress test(NST) and 
amniotic fluid index(AFI)  with infants to be delivered at term. 
 
5. Four times regimen results appears to be significantly better in terms of fetal and maternal 
outcomes across a range of measures as compared to a twice daily insulin regimen. These 
include the extent of maternal glycemic control, mode of delivery as well as the extent of 
hypoglycemia and hyperbilirubinemia in neonates and their Agpar scores.  
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